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AbsTrACT
Objective To assess the current opinion and practice 
patterns from cornea experts regarding the benefit of 
corneal cross-linking (CXL) for infectious keratitis (IK).
Methods and analysis An international survey was 
distributed to corneal specialists via an internet survey. 
The survey data collected were analysed with descriptive 
statistics.
results A survey was sent to 190 recipients, and 
29 (15%) respondents completed the survey with an 
average of 7 years’ experience using CXL. A majority of 
respondents (66%) used CXL to treat IK due to bacterial, 
fungal, protozoan or unknown aetiology. Main indications 
to use CXL as adjuvant therapy were worsening infiltrate 
diameter or depth despite therapy (74%), followed by 
antibiotic resistance (68%), corneal thinning (53%), poor 
compliance with medication (26%) and other reasons 
(21%). Most respondents felt CXL would be at least 
moderately helpful as an adjuvant therapy for bacterial 
(96%) or fungal (75%) keratitis; about half (46%) thought 
it would be helpful for acanthamoeba keratitis. As sole 
therapy, fewer respondents believed CXL would be at least 
moderately helpful to treat bacterial (75%), fungal (58%) 
and acanthamoeba (43%) keratitis.
Conclusion The survey offered insights into current 
expert practices and opinions of using CXL as therapy for 
IK. The results of this survey serve to guide in the design of 
future clinical studies. 
InTrOduCTIOn
Infectious keratitis (IK) is a major cause of 
visual impairment and blindness worldwide.1 
Causative organisms include bacteria, fungi 
and protozoa; treatment is empiric until the 
infectious organism is identified. Delayed 
initiation of appropriate therapy can result 
in poor visual outcomes in up to 30% of IK 
cases.2 Antibiotic resistance, drug availability 
and ocular toxicity complicate treatment regi-
mens for the different types of keratitis and 
practice patterns vary internationally.2–6 
Corneal cross-linking (CXL) may benefit 
patients with infectious corneal ulcers by 
reducing inflammation and inactivating 
infectious organisms simultaneously. CXL 
is currently used as a treatment for corneal 
ectatic disorders such as keratoconus and 
post-LASIK ectasia and has been shown to 
stabilise the cornea and allow it to retain 
its shape.7–9 Photoactivation of riboflavin 
with UV light results in release of reac-
tive oxygen species that promote chemical 
covalent bond formation between adjacent 
collagen molecules.9 10 This may strengthen 
the cornea, increase resistance of corneal 
tissue to enzymatic degradation and reduce 
the risk of corneal melting and perfora-
tion which can complicate IK.10 11 Reactive 
oxygen species are also thought to have an 
antiseptic effect against a broad range of 
pathogens.12 Although there have been three 
small randomised controlled trials to evaluate 
the effect of CXL in the treatment of IK, the 
limitations of these clinical trials and mixed 
results leave the question unanswered.13–15 In 
this survey, we assess corneal experts’ current 
practices and opinions regarding adjuvant 
CXL for IK.
MeThOds
A survey with questions about the use of CXL 
for IK was emailed to experts to assess their 
perspectives and experiences. Experts were 
identified through a search of PubMed for 
manuscripts published between January 2009 
and May 2017 in English-language journals 
that included the terms ‘cornea’, ‘infectious 
keratitis’ and variations of ‘cross-linking’ in 
the title or abstract. Authors’ email addresses 
Key messages
What is already known about this subject?
 ► In vitro studies and case series have suggested that 
adjuvant corneal cross-linking may have a role in the 
treatment of infectious keratitis.
What are the new findings?
 ► Experts believe that corneal cross-linking is a 
beneficial adjuvant for treating infection and 
stabilizing keratolysis, but that it is more effective 
in bacterial infections than fungal or acanthameoba.
how might these results change the focus of 
research or clinical practice?
 ► A well-designed randomized controlled trial is 
necessary to establish the role of corneal cross-
linking in the treatment of corneal ulcers. 
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were extracted with a Perl16 programme from corre-
sponding author information.
An email with an introduction to the survey, a consent 
document and an individualised, anonymous survey 
URL was sent to each participant email address through 
the Research Electronic Data Capture (REDCap) data 
collection tool. The initial invitation was sent by email 
in January 2016 and four reminder emails were sent to 
participants who had not responded. The survey was 
open for a total of 8 weeks.
The questionnaire consisted of the following sections: 
(1) demographic information, (2) clinical experience 
with cross-linking for IK, (3) ideal practice using CXL 
for IK (online supplementary file). Respondents who 
reported experience treating IK with cross-linking were 
posed an additional section regarding (4) the utility of 
cross-linking for each type of infectious organism for 
which they had experience. Respondents were given the 
option to waive anonymity of their survey response to be 
included in the acknowledgements section.
Results were analysed using Stata V.14 (Stata, College 
Station, Texas, USA). This research adhered to the tenets 
of the Declaration of Helsinki.
resulTs
demographics
A literature search of publications on CXL identified 
190 unique, valid email addresses. Twenty-nine (15.3%) 
recipients completed the survey. All survey recipients 
were cornea specialists, with subspecialty training in 
cornea only (n=7; 24%), cornea and refractive (n=19; 
66%) and other subspecialties (n=3; 10%). Respondents 
were from 16 countries, with more from Italy (n=6; 21%) 
and India (n=5; 17%) and others from USA and other 
countries in Europe, South America, the Middle East and 
Australia (figure 1). The most common practice setting 
of respondents was academic (13/29; 45%), followed by 
private practice (9/29; 31%) and government hospitals 
(6/29; 21%) (figure 2). The average (median) number 
of years in practice was 15 years (IQR 8, 25 years) with an 
average (median) of 7 years of experience using CXL on 
patients (IQR 5, 9 years).
The vast majority of respondents reported having used 
CXL for any indication in their clinical practice (28/29; 
97%). More specifically, CXL was used 1–50 times (34%), 
51–150 times (28%) or more than 150 times (34%) in the 
past 12 months.
Current practices
Table 1 summarises respondents’ current practices and 
experience using CXL. The majority of respondents 
(n=19; 68%) had used CXL to treat a patient with IK. 
Of these respondents, organisms treated with CXL were 
diverse and included bacterial ulcers (16/19; 84%), 
fungal ulcers (13/19; 68%), acanthamoebic ulcers 
(12/19; 63%) as well as microbial keratitis of unknown 
aetiology (5/19; 26%). The survey did not ask about viral 
keratitis.
The main indications reported for using CXL for IK 
were worsening infiltrate diameter or depth despite 
therapy (14/19; 74%), followed by antibiotic resistance 
(13/19; 68%), corneal thinning (10/19; 53%), poor 
compliance with medication (5/19; 26%) and other 
reasons (4/19; 21%) (table 1). Most experts (9/19; 
47%) performed CXL 1–4 weeks after the onset of the 
ulcer, 37% (7/19) performed after 4 weeks of onset and 
16% (3/19) performed within 1 week of onset. Respon-
dents performed CXL for IK both in the operating 
room (13/19; 68%) and in the outpatient clinic (8/19; 
42%).
Figure 1 Respondents’ country of practice. *Australia, 
Austria, Brazil, Colombia, Denmark, France, Greece, 
Pakistan, Portugal, Sweden, Switzerland and UK.
Figure 2 Respondents practice setting.
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Ideal practices
Table 2 describes respondents’ opinions on ideal prac-
tices for CXL for IK. Of the respondents that thought 
CXL could be useful to treat IK, 13/24 (54%) said that 
the ideal ulcer location to maximise benefit of CXL does 
not matter, while others (6/24; 25%) felt a centrally 
located (central 4 mm) ulcer would benefit from CXL 
the most and 4/24 (17%) were unsure about the ideal 
ulcer location. Most respondents felt CXL would be 
beneficial for infections with small (17/24; 71%) and 
medium-sized (16/23; 70%) infiltrate diameters but 
fewer (8/23; 35%) thought CXL would be beneficial for 
large infiltrates. When asked about when CXL should be 
ideally performed after the onset of IK, 46% (11/24) of 
respondents reported<1 week of onset of the ulcer, 38% 
(9/24) reported 1–4 weeks of onset and 17% (4/24) were 
unsure. A large majority (21/25; 84%) of respondents 
reported that the main benefit of CXL for IK would be 
microbial eradication, and 15/25 (60%) of respondents 
reported CXL would be beneficial in the prevention of 
corneal thinning.
Table 3 outlines how respondents felt about CXL as 
either an adjuvant therapy (in addition to microbial 
therapy) or as the sole therapy. The majority of respon-
dents (25/28; 89%) reported that they thought CXL 
would be useful in treating IK, although responses to 
follow-up questions showed that opinions varied by type 
of organism. Most respondents reported that CXL as an 
adjuvant therapy would be at least moderately effective 
for bacterial keratitis (23/24; 96%) or fungal keratitis 
(18/24; 75%) with fewer reporting that CXL would be 
at least moderately helpful as an adjuvant therapy for 
acanthamoeba keratitis (11/24; 46%). No respondents 
believed CXL as an adjuvant therapy would be detri-
mental in treating bacterial ulcers, but some believed 
it would be detrimental for fungal (1/24; 4%) or acan-
thamoeba (2/24; 8%) ulcers.
Fewer respondents believed CXL would be at least 
moderately helpful to treat bacterial (18/24; 75%), 
fungal (14/24; 58%) and acanthamoeba (10/23; 43%) 
as the only therapy. Some respondents felt CXL would 
be detrimental in treating bacterial (2/24; 8%), fungal 
(3/24; 13%) or acanthamoeba (4/23; 17%) ulcers if used 
without antimicrobial treatments. More respondents felt 
CXL would have no effect as adjuvant or sole therapy for 
acanthamoeba keratitis when compared with bacterial 
and fungal keratitis (table 3).
An additional section of the questionnaire asked 
respondents who had experience using CXL to treat IK of 
each organism type about their opinions on its effective-
ness in eradicating the infectious organism. Most corneal 
specialists (14/16; 88%) reported CXL was helpful in 
eradicating bacterial ulcers, while 13% (2/16) reported 
no effect. Respondents were split on the effectiveness of 
CXL treating fungal ulcers in their experience, with 46% 
(6/13) reporting that the CXL was at least moderately 
helpful, but 54% (7/13) said the CXL had no effect in 
eradicating the fungus. Similarly, respondents were split 
on acanthamoebic ulcers as well: 50% (6/12) reported 
CXL was at least moderately helpful in eradicating the 
acanthamoeba, and 50% (6/12) said the CXL had no 
effect. All five respondents with experience treating IK 
Table 1 Respondents’ experience with cross-linking for IK
Survey response n/N (%)
Used CXL ever 28/29 (97%)
Used CXL for IK 19/28 (68%)
Think CXL can be useful for IK 25/28 (89%)
Experience with CXL treating IK by type
  Bacterial 16/19 (84%)
  Fungal 13/19 (68%)
  Acanthamoeba 12/19 (63%)
  Unknown organism 5/19 (26%)
Indications for using CXL for IK
  Worsening infiltrate 14/19 (74%)
  Antibiotic resistance 13/19 (68%)
  Corneal thinning 10/19 (53%)
  Poor medication compliance 5/19 (26%)
  Other 4/19 (21%)
CXL, corneal cross-linking; IK, infectious keratitis.
Table 2 Ideal practices of cross-linking for infectious 
keratitis
Survey response n/N (%)
Ideal timing*
  <1 week 11/24 (46%)
  1–4 weeks 9/24 (38%)
  >4 weeks 0/24 (0%)
  Unsure 4/24 (17%)
Ideal ulcer location for CXL*
  Central 6/24 (25%)
  Peripheral 1/24 (4%)
  Does not matter 13/24 (54%)
  Unsure 4/24 (17%)
CXL beneficial by infiltrate size
  Small* 17/24 (71%)
  Medium† 16/23 (70%)
  Large† 8/23 (35%)
Would use CXL for corneal thinning 15/25 (60%)
Would use CXL for non-healing ulcer 12/25 (48%)
Main benefits of CXL
  Microbial eradication 21/25 (84%)
  Prevention of corneal thinning 15/25 (60%)
  Other benefits 3/25 (12%)
*One respondent with missing data.
†Two respondents with missing data.
CXL, corneal cross-linking.
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ulcers infected with unknown organisms reported CXL 
was helpful in eradicating the unknown agent (5/5; 
100%). Of note, no respondents reported that CXL was 
detrimental in their experience treating ulcers of any 
type of infectious organism.
Cost
Cornea specialists were asked about the proportion of 
their patients who were unable to undergo CXL for IK 
due to cost. Patients paid for the entire cost of CXL out of 
pocket in the practices of 39% (7/18) of the respondents, 
with an equal proportion reporting that the hospital 
covered the entire cost of the procedure. Other mecha-
nisms of payment (4/17; 24%) included cost coverage by 
an investigational study or a public health department. 
A little over half of respondents (9/16; 56%) reported 
that CXL is not cost-prohibitive to any of their patients. 
Regardless of how the procedure was paid for, 4/16 
(25%) reported that 20%–50% of their patients could 
not receive CXL due to cost.
dIsCussIOn
In this survey, we found that the majority of corneal 
specialists with CXL experience felt that it would be a 
beneficial adjuvant in the treatment of IK. There was 
much more consensus that CXL is beneficial in bacte-
rial ulcers compared with fungal and acanthamoeba. In 
fact, most respondents reported favourable experiences 
treating bacterial ulcers and felt it would be effective even 
without antimicrobials. Most thought that the benefit of 
CXL was in eliminating infection, but that it may reduce 
corneal melting as well. Our survey revealed that 55% of 
the corneal specialists felt CXL was at least moderately 
helpful in preventing corneal thinning from their experi-
ence, while 33% felt it had no effect.
Multiple case reports have suggested potential bene-
fits of CXL for treatment of bacterial keratitis, including 
resolution of resistant infection, halting of progressive 
melting and symptomatic improvement.17–20 One small 
randomised controlled trial found a benefit to CXL in 
the treatment of bacterial ulcers.14 In another small case 
series, bacterial infections resolved even though patients 
were treated exclusively with photochemically activated 
riboflavin.21 Spoerl et al reported that cornea buttons 
treated with CXL showed increased resistance against 
bacterial collagenase.22
The evidence supporting CXL for fungal and acan-
thamoeba keratitis is less robust. In vitro studies have 
shown that photochemically activated riboflavin inhibits 
bacterial, but not fungi growth, although when CXL was 
combined with amphotericin, there was an effect.23 24 Clin-
ically, Vajpayee et al25 reported equivocal results of CXL 
as an adjuvant therapy compared with medical therapy 
alone in moderate fungal keratitis (defined by diam-
eter<6 mm or involving <60% of corneal thickness) 
through a retrospective review. One small randomised 
clinical trial investigating cross-linking as adjuvant 
therapy for deep fungal ulcers at Aravind Eye Hospital 
in Madurai, India was stopped after only enrolling 13 
patients due to concern that CXL was increasing the rate 
of perforation in severe fungal ulcers.15
Although less well studied, most agree that acan-
thamoeba is unlikely to respond to CXL due to the lack 
of demonstrated in vitro cystocidal activity.26 Published 
results of in vitro and in vivo animal (rabbit and hamster) 
studies showed ultraviolet light A and riboflavin treatment 
failed to demonstrate cystocidal activity as sole therapy.26 27 
However, in vitro and animal models often have high 
inoculation and may not reflect real life situation. On the 
Table 3 Opinions on cross-linking for infectious keratitis by type of organism
Survey response Helpful, n/N (%) No effect, n/N (%) Detrimental, n/N (%)
Adjuvant therapy
  Bacterial 23/24 (96%) 1/24 (4%) 0/24 (0%)
  Fungal 18/24 (75%) 5/24 (21%) 1/24 (4%)
  Acanthamoeba 11/24 (46%) 10/23 (43%) 2/23 (9%)
  Unknown organism – – – 
Sole therapy
  Bacterial 18/24 (75%) 4/24 (17%) 2/24 (8%)
  Fungal 14/24 (58%) 7/24 (29%) 3/24 (13%)
  Acanthamoeba 10/23 (43%) 9/23 (39%) 4/23 (17%)
  Unknown organism – – – 
Experience treating
  Bacterial 14/16 (88%) 2/16 (13%) 0/16 (0%)
  Fungal 6/13 (46%) 7/13 (54%) 0/13 (0%)
  Acanthamoeba 6/12 (50%) 6/12 (50%) 0/12 (0%)
  Unknown organism 5/5 (100%) 0/5 (0%) 0/5 (0%)
5Hsia YC, et al. BMJ Open Ophth 2018;3:e000112. doi:10.1136/bmjophth-2017-000112
Open Access
other hand, case reports on acanthamoeba keratitis in 
humans in which CXL was used as an adjuvant therapy 
showed promising results in advanced cases refractory 
to medical treatment.28–31 These findings suggest CXL 
may not be an effective sole therapy for acanthamoeba, 
but may be useful as an adjuvant therapy potentially by 
limiting stromal degradation and allowing the topical 
therapies to eliminate the acanthamoeba. The low inci-
dence and prevalence of the disease makes it difficult to 
conduct a randomised controlled trial. In a meta-anal-
ysis by Papaioannou et al,32 results were limited to draw 
a conclusion on the value of CXL for acanthamoeba or 
fungal keratitis.
Strengths of this study include the geographic diversity 
of respondents, representing a broad range of experience 
and international perspectives. Additionally, a majority 
of respondents have experience using CXL to treat IK 
of varying aetiologies, particularly striking given that 
acanthamoeba and fungal keratitis are statistically rare. 
Limitations of this study include a lower response rate of 
15.3%. However, this rate is higher than other web-based 
international surveys of experts in ophthalmology,33–35 
and the number of responses reflecting unfavourable 
opinions on cross-linking for IK suggest we did not only 
survey advocates of the treatment method. Because 
experts were identified through a search of published 
literature, experts in cross-linking for IK may have been 
missed if they had not published on the topic. The 
majority of respondents in our study work in an academic 
practice setting, so the results may not be generalisable 
to all clinical ophthalmologists. Nevertheless, specialists 
are likely to treat the majority of severe IK cases. Because 
the use of CXL for IK is currently not approved by the US 
Federal Drug Administration, respondents were mostly 
corneal specialists outside of USA, suggesting our survey 
may be influenced by selection and/or response bias. 
Additional limitations include branching logic format-
ting of the survey such that not all questions appeared 
for all respondents and those intrinsic to all surveys, 
including non-response bias and the possibility of recall 
bias.
COnClusIOn
Corneal specialists who have used CXL overall agree that 
it may be beneficial in the treatment of bacterial ulcers 
that are small to medium in size. However, the majority 
remain unsure regarding the efficacy of CXL on fungal 
and protozoan keratitis. Additionally, a quarter of respon-
dents reported a moderate proportion of their patients 
could not undergo CXL due to cost, indicating that work 
still needs to be done to improve access to the procedure. 
The survey suggests that larger, well-designed randomised 
controlled trials would be of interest to corneal specialists 
to assess the efficacy of CXL as adjuvant therapy for IK.
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